title: A report from The Liver Meeting 2014 (November 7-11 - Boston, Massachusetts, USA).
abstract: The first waves of winter cold were sweeping across Massachusetts at the time this year's American Academy for the Study of Liver Diseases' Liver Meeting opened gates to a crowd of scientists and researchers from across the globe. The Hynes Convention Center acted as the liver through which new research from many different sources, shaped as oral and poster presentations, was transformed into a story of hope for new, more effective treatments for common liver diseases, particularly viral hepatitis infection and nonalcoholic steatohepatitis. As summarized in the following report, novel research was also reported emphasizing novel potential therapies for liver cancer as well as a broad range of liver diseases.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D000818:Animals; D006509:Hepatitis B / Q000188:drug therapy; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy; D008107:Liver Diseases / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000188:drug therapy; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy
keywords: Hepatitis B virus infection; Hepatitis C virus infection; Liver cancer; Nonalcoholic steatohepatitis; Primary biliary cirrhosis